Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2013-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72196d4a5725d9518749b5895c0b6be5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d0424b0d2f959a43f5e3117b77f0010 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a08d8ca9ba27e25fb9595cc4a6a623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b09f872c6595b79da3548de3c6f91249 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015868381297b286a78581565fa7b57f |
publicationDate |
2014-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014377261-A1 |
titleOfInvention |
Vaccines against antigens involved in therapy resistance and methods of using same |
abstract |
Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842857-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253580-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11235043-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842855-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017120576-A1 |
priorityDate |
2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |